Heering Jan, Merk Daniel
Branch for Translational Medicine and Pharmacology TMP, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Frankfurt, Germany.
Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH) Zürich, Zürich, Switzerland.
Methods Mol Biol. 2019;1966:175-192. doi: 10.1007/978-1-4939-9195-2_14.
Nuclear receptors act as ligand-activated transcription factors translating ligand signals into changes in gene expression. The 48 members of the superfamily of nuclear receptors identified so far are involved amongst others in maintenance of metabolic balance, inflammation, and cancer. Thus, they hold enormous potential for drug discovery and some nuclear receptors are experiencing considerable academic and industrial interest. Nuclear receptor modulator discovery requires reliable, robust, and economic test systems that allow for high throughput. In this chapter, we discuss the principle, strengths, and advantages of hybrid reporter gene assays for nuclear receptor focused drug discovery and describe how they can be developed, established, and validated.
核受体作为配体激活的转录因子,将配体信号转化为基因表达的变化。迄今为止确定的核受体超家族的48个成员参与维持代谢平衡、炎症和癌症等过程。因此,它们在药物发现方面具有巨大潜力,一些核受体正受到学术界和工业界的广泛关注。核受体调节剂的发现需要可靠、稳健且经济的高通量测试系统。在本章中,我们将讨论用于聚焦核受体药物发现的杂交报告基因检测的原理、优点及优势,并描述如何开发、建立和验证这些检测方法。